Liver involvement in early autosomal-dominant polycystic kidney disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 1, 2015, Pages 155-164.e6

  Hogan, Marie C ^a   Abebe, Kaleab ^b   Torres, Vicente E ^a   Chapman, Arlene B ^c   Bae, Kyongtae T ^b   Tao, Cheng ^b   Sun, Hongliang ^b   Perrone, Ronald D ^d   Steinman, Theodore I ^e   Braun, William ^f   Winklhofer, Franz T ^g   Miskulin, Dana C ^d   Rahbari Oskoui, Frederic ^c   Brosnahan, Godela ^h   Masoumi, Amirali ^h   Karpov, Irina O ^b   Spillane, Susan ^b   Flessner, Michael ⁱ   Moore, Charity G ^b   Schrier, Robert W ^h  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

CKD; HALT PKD A; Hepatic cyst; MRI analysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GROUPS BY AGE; HEPATOMEGALY; HUMAN; HYPERSPLENISM; HYPERTENSION; HYPOTENSION; KIDNEY CYST; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; LIVER CYST; LIVER PARENCHYMA; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; ADOLESCENT; COMPLICATION; LIVER; LIVER FUNCTION TEST; MIDDLE AGED; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATOMEGALY; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84916900344     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.07.051     Document Type: Article

References (40)

1. Gabow P.A. Autosomal dominant polycystic kidney disease. NEngl J Med 1993, 329:332-342.
2. US Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013. Accessed: May 8,2013.
3. Everson G.T., Taylor M.R., Doctor R.B. Polycystic disease of the liver. Hepatology 2004, 40:774-782.
4. Comfort M.W., Gray H.K., Dahlin D.C., et al. Polycystic disease of the liver: a study of 24 cases. Gastroenterology 1952, 20:60-78.
5. Chauveau D., Fakhouri F., Grunfeld J.P. Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. JAm Soc Nephrol 2000, 11:1767-1775.
6. Everson G.T. Hepatic cysts in autosomal dominant polycystic kidney disease. Mayo Clin Proc 1990, 65:1020-1025.
7. Patch C., Charlton J., Roderick P.J., et al. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011, 57:856-862.
8. Orskov B., Romming Sorensen V., Feldt-Rasmussen B., et al. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2010, 5:2034-2039.
9. Orskov B., Sorensen V.R., Feldt-Rasmussen B., et al. Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2012, 27:1607-1613.
10. Perrone R.D., Abebe K.Z., Schrier R.W., et al. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011, 6:2508-2515.
11. Ecder T., Edelstein C.L., Chapman A.B., et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999, 14:1113-1116.
12. Keimpema L.V., Nevens F., Vanslembrouck R., et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009, 137:1661-1668. e1-2.
13. Caroli A., Antiga L., Cafaro M., et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 2010, 5:783-789.
14. Hogan M.C., Masyuk T.V., Page L.J., et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. JAm Soc Nephrol 2010, 21:1052-1061.
15. Hogan M.C., Masyuk T.V., Page L., et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012, 27:3532-3539.
16. Gevers T.J.G., IntHout J., Caroli A., et al. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology 2013, 145:357-365. e1-2.
17. Chrispijn M., Gevers T.J., Hol J.C., et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. JHepatol 2013, 59:153-159.
18. Chapman A.B., Torres V.E., Perrone R.D., et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010, 5:102-109.
19. Torres V.E., Chapman A.B., Perrone R.D., et al. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 2012, 81:577-585.
20. Geraghty E.M., Boone J.M., McGahan J.P., et al. Normal organ volume assessment from abdominal CT. Abdom Imaging 2004, 29:482-490.
21. Heinemann A., Wischhusen F., Püschel K., et al. Standard liver volume in the Caucasian population. Liver Transplant Surg 1999, 5:366-368.
22. Vauthey J.N., Abdalla E.K., Doherty D.A., et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002, 8:233-240.
23. Perrone R.D., Ruthazer R., Terrin N.C. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis 2001, 38:777-784.
24. Bae K.T., Zhu F., Chapman A.B., et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006, 1:64-69.
25. Schnelldorfer T., Torres V.E., Zakaria S., et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009, 250:112-118.
26. Everson G.T., Scherzinger A., Berger-Leff N., et al. Polycystic liver disease: quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts. Hepatology 1988, 8:1627-1634.
27. Itai Y., Ebihara R., Eguchi N., et al. Hepatobiliary cysts in patients with autosomal dominant polycystic kidney disease: prevalence and CT findings. AJR Am J Roentgenol 1995, 164:339-342.
28. Gupta S., Seith A., Dhiman R.K., et al. CT of liver cysts in patients with autosomal dominant polycystic kidney disease. Acta Radiol 1999, 40:444-448.
29. Nagy P., Teramoto T., Factor V.M., et al. Reconstitution of liver mass via cellular hypertrophy in the rat. Hepatology 2001, 33:339-345.
30. Hopp K., Hommerding C.J., Wang X., et al. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. JAm Soc Nephrol 2014, Epub ahead of print.
31. Torra R., Nicolau C., Badenas C., et al. Ultrasonographic study of pancreatic cysts in autosomal dominant polycystic kidney disease. Clin Nephrol 1997, 47:19-22.
32. Malka D., Hammel P., Vilgrain V., et al. Chronic obstructive pancreatitis due to a pancreatic cyst in a patient with autosomal dominant polycystic kidney disease. Gut 1998, 42:131-134.
33. Mosetti M.A., Leonardou P., Motohara T., et al. Autosomal dominant polycystic kidney disease: MR imaging evaluation using current techniques. JMagn Reson Imaging 2003, 18:210-215.
34. Ishikawa I., Chikamoto E., Nakamura M., et al. High incidence of common bile duct dilatation in autosomal dominant polycystic kidney disease patients. Am J Kidney Dis 1996, 27:321-326.
35. Gordon D.B. The role of renin substrate in hypertension. Hypertension 1983, 5:353-362.
36. Ramkumar N., Stuart D., Ying J., et al. Apossible interaction between systemic and renal angiotensinogen in the control of blood pressure. Am J Hypertens 2013, 26:473-480.
37. Gabow P.A., Johnson A.M., Kaehny W.D., et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990, 11:1033-1037.
38. Sherstha R., McKinley C., Russ P., et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 1997, 26:1282-1286.
39. Zollner F.G., Svarstad E., Munthe-Kaas A.Z., et al. Assessment of kidney volumes from MRI: acquisition and segmentation techniques. AJR Am J Roentgenol 2012, 199:1060-1069.
40. Wijnands T.F., Neijenhuis M.K., Kievit W., et al. Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int 2014, 34:1578-1583.